Tandem diabetes care, inc.TNDM.US Overview
TNDM Overall Performance
TNDM AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
TNDM Current Performance
0.48%
Tandem diabetes care, inc.
1.03%
Avg of Sector
0.27%
S&P500
TNDM Key Information
TNDM Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
TNDM Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
TNDM Profile
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Price of TNDM
TNDM FAQ
When is TNDM's latest earnings report released?
The most recent financial report for Tandem diabetes care, inc. (TNDM) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TNDM's short-term business performance and financial health. For the latest updates on TNDM's earnings releases, visit this page regularly.
What is the operating profit of TNDM?
According to the latest financial report, Tandem diabetes care, inc. (TNDM) reported an Operating Profit of -51.81M with an Operating Margin of -21.53% this period, representing a decline of 68.36% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is TNDM's revenue growth?
In the latest financial report, Tandem diabetes care, inc. (TNDM) announced revenue of 240.68M, with a Year-Over-Year growth rate of 8.46%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does TNDM have?
As of the end of the reporting period, Tandem diabetes care, inc. (TNDM) had total debt of 449.01M, with a debt ratio of 0.51. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does TNDM have?
At the end of the period, Tandem diabetes care, inc. (TNDM) held Total Cash and Cash Equivalents of 64.11M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does TNDM go with three margins increasing?
In the latest report, Tandem diabetes care, inc. (TNDM) did not achieve the “three margins increasing” benchmark, with a gross margin of 52.3%%, operating margin of -21.53%%, and net margin of -21.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TNDM's profit trajectory and future growth potential.
Is TNDM's EPS continuing to grow?
According to the past four quarterly reports, Tandem diabetes care, inc. (TNDM)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TNDM?
Tandem diabetes care, inc. (TNDM)'s Free Cash Flow (FCF) for the period is -15.7M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 33.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TNDM?
The latest valuation data shows Tandem diabetes care, inc. (TNDM) has a Price-To-Earnings (PE) ratio of -4.73 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.